NHS to fast-track cancer drugs that target genetic mutations

The NHS is preparing to fast-track the introduction of ‘game changing’ new cancer drugs that target tumours according to their genetic make-up. These revolutionary new treatments, called ‘tumour agnostic’ drugs, can be used against a wide range of cancers and could offer hope to patients with rare cancers that may previously have been untreatable. Tumour […]

read more

Cytoreductive surgery with immunotherapy for kidney cancer patients

In this video clip, Professor Eric Jonasch, Medical Oncologist, Division of Cancer Medicine at MD Anderson Cancer Center, University of Texas, Houston, speaks about the role of cytoreductive surgery along with immunotherapy for patients who have metastatic renal cell carcinoma (RCC). Watch the video on Practice Update here

read more

Radical versus partial nephrectomy and subsequent hypertension risk

In a recent study, the data from a database were analysed retrospectively to evaluate the onset or worsening of high blood pressure (hypertension) following partial versus radical nephrectomy. 3106 patients who did not have hypertension before nephrectomy had an increased risk of developing hypertension after radical nephrectomy. In 6250 patients who already had hypertension, radical […]

read more

Nivolumab-ipilimumab combination shows promise for kidney cancer brain metastases

An interim analysis of study Checkmate 920 has shown that patients with advanced renal cell carcinoma (RCC) and brain metastases may benefit from treatment with the ipilimumab/nivolumab combination therapy. The results from this interim analysis were presented at the 2019 American Society of Clinical Oncology (ASCO) in Chicago earlier this month. Read more in Cancer […]

read more

Genetic mutations associated with survival in immunotherapy-treated kidney cancer patients

A recent study of patients with solid tumours treated with immune checkpoint inhibitors has shown improved overall survival in patients who had mutations in the genes that code for a group of proteins involved in the way DNA is packaged in the cell (SWI and SNF genes, BRG1/hBRM-associated factor (BAF) and polybromo-BAF (PBAF)). The researchers […]

read more

Long-term surveillance of small renal masses is safe

In a recent study published in Journal of Urology and involving over 100 mostly older patients, almost all of the patients with small kidney tumours never developed advanced cancer or died of the disease during more than 4 years of follow-up in active surveillance. More than half of the patients remained alive without metastatic disease […]

read more

Patient reported experience for patients with kidney cancer

In this video interview from Practice Update, Dr Eric Jonasch, board member for the International Kidney Cancer Coalition (IKCC), talks about the results from the recent global survey involving nearly 2,000 kidney cancer patients. Some of the key findings from this survey were; a significant percentage of patients did not know the histology of their […]

read more

Stereotactic radiosurgery is successful for RCC brain metastases

A recent study of 362 patients with brain metastases from renal cell carcinoma (RCC) were treated with stereotactic radiosurgery to remove the metastases. The researchers concluded that stereotactic radiosurgery is highly effective in patients with brain metastases from RCC, and concomitant use of tyrosine kinase inhibitors (TKIs), such as sunitinib and pazopanib, does not suggest […]

read more

Low PD-L1 associated with long term response to sunitinib

Researchers from France have conducted a study to show that metastatic clear cell renal cell carcinoma (RCC) patients who have low expression of PD-L1 also have a long term response to sunitinib. However, low PD-L1 levels suggest a potentially lower impact of immunotherapy in these patients. Read more in Clinical Genitourinary Cancer here

read more

SMC approves nivolumab plus ipilimumab combination for advanced RCC

We are delighted to announce that the Scottish Medicines Consortium (SMC), which reviews newly licensed medicines in Scotland, has published advice recommending the routine use of nivolumab plus ipilimumab for intermediate-/poor-risk advanced renal cell carcinoma (RCC) by NHS Scotland. The nivolumab (Opdivo) plus ipilimumab (Yervoy) combination was accepted following consideration through the SMC’s Patient and […]

read more
Showing 21 to 30 of 567 results
  TOP